<DOC>
	<DOCNO>NCT01889862</DOCNO>
	<brief_summary>The BMN 165 clinical development program design demonstrate safety efficacy BMN 165 reduce blood Phe concentration adult PKU .</brief_summary>
	<brief_title>Phase 3 Study Evaluate Efficacy &amp; Safety Self-Administered Injections BMN165 Adults With PKU</brief_title>
	<detailed_description>165-302 Phase 3 , 4 Part , Randomized , Double-Blind , Placebo-Controlled , Discontinuation Study Evaluate Efficacy Safety Self Administered Subcutaneous Injections BMN 165 Adults With PKU . This study open adult expose BMN165 previous study . Study BMN 165-302 four-part , Phase 3 study . - PART 1 : Open-label period - PART 2 : A Randomized , double-blind , placebo-controlled period 8 week - PART 3 : PK ( plasma BMN 165 ) PD ( plasma Phe ) assessment . - Part 4 : A long-term , open-label extension study .</detailed_description>
	<mesh_term>Phenylketonurias</mesh_term>
	<criteria>INCLUSION CRITERIA Individuals eligible participate study must meet following criterion : Have complete prior BMN 165 study ( PAL003 165301 ) prior screen Have stable BMN 165 dose regimen least 14 day prior screen Are least 18 y/o old 70 y/o screen Subjects &lt; 18 y/o already enrol Study 165301 Amendment # 1 ( 10JAN2014 ) may enroll study Has identify person ≥ 18 y/o neurocognitive linguistic capacity comprehend complete POMSObserver rat scale Has identify competent person ( ) ≥ 18 y/o observe subject study drug administration certain point study A home healthcare nurse may perform study drug observation Are willing able provide write , sign informed consent nature study explain prior researchrelated procedure ; minor , parent guardian provide write consent assent may request Are willing able comply study procedure For female childbearing potential , negative pregnancy test screen willing additional pregnancy test study If sexually active , willing use two acceptable method contraception 4 week study Males post vasectomy 2 year know pregnancy need use form contraception study . Females menopause least 2 year , tubal ligation least 1 year prior screening , total hysterectomy need use form contraception study . Have receive document approval study dietitian confirm subject capable maintain diet Have neurocognitive linguistic capacity comprehend answer investigator 's prompt ADHDRS Investigator rat instrument complete POMSSubject rat scale If applicable , maintain stable dose medication ADHD , depression , anxiety , psychiatric disorder ≥8 week prior enrollment willing maintain stable dose throughout study unless change medically indicated General good health , evidence physical examination , clinical laboratory evaluation , ECG test screen Exclusion Criteria Individuals meet follow exclusion criterion eligible participate study : Use investigational product ( except BMN 165 ) investigational medical device within 30 day prior screen requirement investigational agent prior completion schedule study assessment Use medication ( except BMN 165 ) intend treat PKU , include use large neutral amino acid , within 2 day prior administration study drug Have know hypersensitivity Dextran® component Dextran Use plan use injectable drug contain PEG ( except BMN 165 ) , include medroxyprogesterone injection , within 3 month prior screen study participation Current use levodopa A positive test HIV antibody , hepatitis B surface antigen , hepatitis C antibody A history organ transplantation take chronic immunosuppressive therapy A history substance abuse past 12 month current alcohol drug abuse Current participation Kuvan registry study ( PKUDOS ) . Patients may discontinue PKUDOS registry trial allow enrollment study Pregnant breastfeed screen plan become pregnant ( self partner ) breastfeed time study Concurrent disease condition would interfere study participation safety . Major surgery plan study period Any condition view investigator , place subject high risk poor treatment compliance terminate early study ALT concentration least 2x upper limit normal Creatinine least 1.5x upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>PKU</keyword>
	<keyword>PEG-PAL</keyword>
	<keyword>Prism</keyword>
	<keyword>BioMarin</keyword>
	<keyword>rAvPAL-PEG</keyword>
	<keyword>Pegvalaise</keyword>
</DOC>